Newer therapeutic approaches to the vasculitides: Biologic agents

Rheumatic Disease Clinics of North America

Volumn 32, Issue 1, 2006, Pages 187-200

  Samuels, Jonathan ^a   Spiera, Robert ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; PEGINTERFERON; PREDNISONE; RIBAVIRIN; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSENCE OF SIDE EFFECTS; ANCA ASSOCIATED VASCULITIS; AORTA ARCH SYNDROME; ARTERY THROMBOSIS; BEHCET DISEASE; BONE MARROW TOXICITY; CATARACT; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CRYOGLOBULINEMIA; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDUCED CANCER; FLU LIKE SYNDROME; FRAGILITY FRACTURE; GIANT CELL ARTERITIS; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION; LEUKOCYTOCLASTIC VASCULITIS; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEUROLOGIC DISEASE; ORGAN INJURY; POLYARTERITIS NODOSA; PRIORITY JOURNAL; RETINA ARTERY OCCLUSION; REVIEW; RHEUMATIC POLYMYALGIA; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LAMIVUDINE; RECEPTORS, TUMOR NECROSIS FACTOR; RIBAVIRIN; VASCULITIS;

EID: 33244498198     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2005.09.002     Document Type: Review

References (66)

1. A.S. Fauci, S.M. Wolff, and J.S. Johnson Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis N Engl J Med 285 27 1971 1493 1496
2. M. Field, A. Cook, and G. Gallagher Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis Rheumatol Int 17 3 1997 113 118
3. F. Cantini, L. Niccoli, and C. Salvarani Treatment of longstanding active giant cell arteritis with infliximab: report of four cases Arthritis Rheum 44 12 2001 2933 2935
4. P. Airo, C.M. Antonioli, and M. Vianelli Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs Rheumatology (Oxford) 41 3 2002 347 349
5. A.P. Andonopoulos, N. Meimaris, and D. Daoussis Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis Ann Rheum Dis 62 11 2003 1116
6. A.P. Rozin Infliximab efficiency and failure Ann Rheum Dis 63 6 2004 751 752
7. G.S. Hoffman, M.C. Cid, and C.M. Weyand Phase II study of the safety and efficacy of infliximab in giant cell arteritis (GCA): 22 week interim analysis Arthritis Rheum 52 2005 S271
8. A.L. Tan, J. Holdsworth, and C. Pease Successful treatment of resistant giant cell arteritis with etanercept Ann Rheum Dis 62 4 2003 373 374
9. W.P. Docken Treatment of resistant giant cell arteritis with etanercept Ann Rheum Dis 63 4 2004 469
10. C. Salvarani, F. Cantini, and L. Niccoli Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study J Rheumatol 30 4 2003 760 763
11. C. Salvarani, C. Manzini, and G. Paolazzi Infliximab in the treatment of polmyalgia rheumatica: a double blind, randomized, placebo controlled study Arthritis Rheum 52 2005 S676 S677
12. P. Liang, and G.S. Hoffman Advances in the medical and surgical treatment of Takayasu arteritis Curr Opin Rheumatol 17 1 2005 16 24
13. G.S. Hoffman, P.A. Merkel, and R.D. Brasington Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis Arthritis Rheum 50 7 2004 2296 2304
14. A.D. Rossa, A. Tavoni, and G. Merlini Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent? Rheumatology (Oxford) 44 8 2005 1074 1075
15. H.L. Janssen, M. van Zonneveld, and A.B. van Nunen Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome Eur J Gastroenterol Hepatol 16 8 2004 801 807
16. P. Deleavel, P. Stadler, and E. Descombes Life threatening complications of hepatitis B virus-related polyarteritis nodosa developing despite interferon-alpha therapy Clin Rheumatol 20 2001 290 292
17. L. Guillevin, A. Mahr, and P. Cohen Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa Arthritis Rheum 51 3 2004 482 487
18. C.L. Christian Treatment of polyarteritis nodosa: comment on the article by Guillevin et al Arthritis Rheum 51 6 2004 1060 1061
19. J.E. Weiss, B.A. Eberhard, and D. Chowdhury Infliximab as a novel therapy for refractory Kawasaki disease J Rheumatol 31 4 2004 808 810
20. J.C. Burns, W.H. Mason, and S.B. Hauger Infliximab treatment for refractory Kawasaki syndrome J Pediatr 146 5 2005 662 667
21. G.S. Hoffman, G.S. Kerr, and R.Y. Leavitt Wegener's Granulomatosis: an analysis of 158 patients Ann Intern Med 116 6 1992 488 498
22. J.H. Stone, M.L. Uhlfelder, and D.B. Hellmann Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety Arthritis Rheum 44 2001 1149 1154
23. P. Bartolucci, J. Ramanoelina, and P. Cohen Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients Rheumatology (Oxford) 41 2002 1126 1132
24. P. Lamprecht, J. Voswinkel, and T. Lilienthal Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis Rheumatology (Oxford) 41 11 2002 1303 1307
25. A.D. Booth, P.A. Bacon, and M.E. Griffith Infliximab in ANCA-associated vasculitis: the "ACTIVE" trial Kidney Blood Press Res 26 2003 292 293
26. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group Etanercept plus standard therapy for Wegener's granulomatosis N Engl J Med 352 4 2005 351 361
27. U. Specks, F.C. Fervenza, and T.J. McDonald Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy Arthritis Rheum 44 12 2001 2836 2840
28. K.A. Keogh, M.E. Wylam, and J.H. Stone Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis Arthritis Rheum 52 1 2005 262 268
29. P. Eriksson Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab J Intern Med 257 6 2005 540 548
30. E. Tatsis, A. Schnabel, and W.L. Gross Interferon-alpha treatment of four patients with the Churg-Strauss syndrome Ann Intern Med 129 1998 370 374
31. C. Kroegel, B. Mock, and A. Reissig Interferons and their application in lung diseases Chest 124 6 2003 2406
32. H.U. Simon, H. Seelbach, R. Ehmann, and M. Schmitz Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma Allergy 58 12 2003 1250 1255
33. B. Hellmich, and W.L. Gross Recent progress in the pharmacotherapy of Churg-Strauss syndrome Expert Opin Pharmacother 5 1 2004 25 35
34. O. Arbach, W.L. Gross, and A. Gause Treatment of refractory Churg-Strauss Syndrome (CSS) by TNF-alpha blockade Immunobiology 206 5 2002 496 501
35. L. Unger, M. Kayser, and H.G. Nusslein Successful treatment of severe rheumatoid vasculitis by infliximab Ann Rheum Dis 62 2003 587 588
36. A.A. den Broeder, F.H. van den Hoogen, and L.B. van de Puttle Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to tumour necrosis factor alpha blocking treatment Ann Rheum Dis 60 2001 538 539
37. D.J. Armstrong, M.T. McCarron, and G.D. Wright Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab J Rheumatol 32 4 2005 759
38. N.A. Galaria, V.P. Werth, and H.R. Shumacher Leukocytoclastic vasculitis due to etanercept J Rheumatol 27 2000 2041 2043
39. S.J. Jarrett, G. Cunnane, and P.G. Conaghan Anti-tumor necrosis factor therapy-induced vasculitis: case series J Rheumatol 30 2003 2287 2291
40. M.P. Tusscher, P.J. Jacobs, and M.J. Busch Bilateral anterior toxic optic neuropathy and the use of infliximab BMJ 326 7389 2003 579
41. P. Richette, P. Dieude, and J. Damiano Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis J Rheumatol 31 10 2004 2079 2081
42. P. Richette, and T. Bardin Successful treatment of rheumatoid vasculitis-associated foot drop with Infliximab: Drs. Richette and Bardin reply J Rheumatol 32 4 2005 759
43. P.A. Livermore, and K.J. Murray Anti-tumour necrosis factor therapy associated with cutaneous vasculitis Rheumatology (Oxford) 41 2002 1450 1452
44. G. Cunnane, M. Warnock, and K.H. Fye Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis Arthritis Rheum 47 2002 445 449
45. M.E. McCain, R.J. Quinet, and W.E. Davis Etanercept and infliximab associated with cutaneous vasculitis Rheumatology (Oxford) 41 2002 116 117
46. N. Mohan, E.T. Edwards, and T.F. Cupps Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents J Rheumatol 31 2004 1955 1958
47. L. Guillevin, and L. Mouthon Tumor necrosis factor-alpha blockade and the risk of vasculitis J Rheumatol 31 10 2004 1885 1887
48. C. Ferri, E. Marzo, and G. Longombardo Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial Blood 81 5 1993 1132 1136
49. R. Misiani, P. Bellavita, and D. Fenili Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus N Engl J Med 330 11 1994 751 756
50. C. Donada, A. Crucitti, and V. Donadon Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia Blood 92 8 1998 2983 2984
51. E. Zuckerman, D. Keren, and G. Slobodin Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha J Rheumatol 27 9 2000 2172 2178
52. J.L. Calleja, A. Albillos, and R. Moreno-Otero Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia Aliment Pharmacol Ther 13 9 1999 1179 1186
53. P. Cacoub, O. Lidove, and T. Maisonobe Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis Arthritis Rheum 46 12 2002 3317 3326
54. P. Cacoub, D. Saadoun, and N. Limal PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis Arthritis Rheum 52 3 2005 911 915
55. C. Mazzaro, F. Zorat, and M. Caizzi Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study J Hepatol 42 5 2005 632 638
56. F. Zaja, D. Russo, and G. Fuga Rituximab for the treatment of type II mixed cryoglobulinemia Haematologica 84 12 1999 1157 1158
57. P. Lamprecht, C. Lerin-Lozano, and H. Merz Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis Ann Rheum Dis 62 12 2003 1230 1233
58. D. Sansonno, V. De Re, and G. Lauletta Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20 Blood 101 10 2003 3818 3826
59. B. Turan, H. Gallati, and H. Erdi Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behcet's disease; soluble TNFR-75 as a biological marker of disease activity J Rheumatol 24 1 1997 128 132
60. C. Evereklioglu, H. Er, and Y. Turkoz Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease Mediators Inflamm 11 2 2002 87 93
61. P.P. Sfikakis, P.H. Kaklamanis, and A. Elezoglou Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease Ann Intern Med 140 5 2004 404 406
62. S. Ohno, S. Nakamura, and S. Hori Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis J Rheumatol 31 7 2004 1362 1368
63. M. Melikoglu, I. Fresko, and C. Mat Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study J Rheumatol 32 1 2005 98 105
64. J.T. Rosenbaum Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behcet's disease J Rheumatol 31 7 2004 1241 1243
65. E. Alpsoy, C. Durusoy, and E. Yilmaz Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study Arch Dermatol 138 4 2002 467 471
66. I. Kotter, M. Zierhut, and A.K. Eckstein Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis Br J Ophthalmol 87 4 2003 423 431